Cargando…

Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study

Early molecular response is associated with improved probability of deep molecular response and superior survival in patients with CML-CP. However, ~1 in 3 patients on first-line imatinib do not achieve this threshold. The phase 2b DASCERN trial (NCT01593254) assessed the outcome of early switch to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cortes, Jorge E., Jiang, Qian, Wang, Jianxiang, Weng, Jianyu, Zhu, Huanling, Liu, Xiaoli, Hochhaus, Andreas, Kim, Dong-Wook, Radich, Jerald, Savona, Michael, Martin-Regueira, Patricia, Sy, Oumar, Gurnani, Renuka, Saglio, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387297/ https://www.ncbi.nlm.nih.gov/pubmed/32265500 http://dx.doi.org/10.1038/s41375-020-0805-1

Ejemplares similares

BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
por: Hughes, T P, et al.
Publicado: (2015)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Dasatinib in imatinib‐resistant or ‐intolerant chronic‐phase, chronic myeloid leukemia patients: 7‐year follow‐up of study CA180‐034
por: Shah, Neil P., et al.
Publicado: (2016)

Primary imatinib failure rescued by dasatinib and maintained by reintroduction of imatinib
por: Kumar, Rajiv, et al.
Publicado: (2017)

Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009)

First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
por: Wei, Guoqing, et al.
Publicado: (2010)

Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia
por: Tadesse, Fisihatsion, et al.
Publicado: (2021)

Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study
por: Gemelli, Maria, et al.
Publicado: (2020)

Imatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host disease
por: Sánchez-Ortega, Isabel, et al.
Publicado: (2016)

Dasatinib/imatinib: Treatment failure: case report
Publicado: (2022)

Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison
por: Glauche, Ingmar, et al.
Publicado: (2018)

An economic analysis of high-dose imatinib, dasatinib, and nilotinib for imatinib-resistant chronic phase chronic myeloid leukemia in China: A CHEERS-compliant article
por: Wu, Bin, et al.
Publicado: (2017)

Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
por: Ottmann, Oliver, et al.
Publicado: (2018)

Reply: The long-term response to imatinib treatment of CML
por: Michor, F
Publicado: (2007)

The combination therapy of imatinib and dasatinib achieves long-term molecular response in two imatinib-resistant and dasatinibintolerant patients with advanced chronic myeloid leukemia
por: Zhu, Yu, et al.
Publicado: (2016)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
por: Narita, Miwako, et al.
Publicado: (2010)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Patient Adherence and Persistence with Imatinib, Nilotinib, Dasatinib in Clinical Practice
por: Santoleri, Fiorenzo, et al.
Publicado: (2013)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches
por: Valent, Peter
Publicado: (2007)

Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients
por: Tiribelli, Mario, et al.
Publicado: (2018)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
por: Millot, Frédéric, et al.
Publicado: (2021)

Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
por: Obr, Adam, et al.
Publicado: (2014)

Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: long-term observation in CML Study IV
por: Miranda, M B, et al.
Publicado: (2016)

MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients
por: Harrach, S, et al.
Publicado: (2016)

Combination of panobinostat with ponatinib synergistically overcomes imatinib‐resistant CML cells
por: Matsuda, Yasufumi, et al.
Publicado: (2016)

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants
por: Hehlmann, R, et al.
Publicado: (2017)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Correction: Real-Time Analysis of Imatinib- and Dasatinib-Induced Effects on Chronic Myelogenous Leukemia Cell Interaction with Fibronectin
Publicado: (2014)

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance
por: Zhang, Jingru, et al.
Publicado: (2018)

SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation
por: Giallongo, Cesarina, et al.
Publicado: (2013)

Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib
por: Stella, Stefania, et al.
Publicado: (2019)

Cytopenia among CML Patients on Imatinib in Kenya: Types, Grades, and Time Course
por: McLigeyo, Angela, et al.
Publicado: (2020)

Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase
por: Chuah, Charles T., et al.
Publicado: (2014)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
por: Al-Amleh, Esraa K., et al.
Publicado: (2022)

Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells
por: Liu, Juan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kaev2bs0gau0hej7sl6s40hr4r